참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 1-Bromo-4-iodobenzene | HCID 11522 | — |
| 반응물 | 1,4'-Bipiperidine | HCID 78607 | — |
| 시약 | Sodium t-butoxide | HCID 23676156 | — |
| 촉매 | 1,1'-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis(1,1-diphenylphosphine) | HCID 636044 | — |
| 촉매 | Bis(dibenzylideneacetone)palladium | HCID 9811564 | — |
| 용매 | Toluene | HCID 1140 | — |
| 생성물 | 1-(4-Bromophenyl)-4-piperidin-1-ylpiperidine | HCID 23130821 | 64.41% |
반응 단계
TRIS(DIBENZYLIDENEACETONE)DIPALLADIUM(0) (0.162 g, 0.18 mmol) was added to 1,4'-bipiperidine (0.595 g, 3.53 mmol), 1-bromo-4-iodobenzene (1.000 g, 3.53 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (0.205 g, 0.35 mmol) and sodium 2-methylpropan-2-olate (0.408 g, 4.24 mmol) in toluene (10 mL). The resulting mixture was degassed again and was stirred at 80 °C for 18 hours under nitrogen. The reaction mixture was cooled to room temperature and filtered then the filtrate was diluted with EtOAc (50 mL), and washed sequentially with water (50 mL), water (50 mL), and saturated brine (50 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford 1'-(4-bromophenyl)-1,4'-bipiperidine (0.736 g, 64.4 %) as a pale brown oil.
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-1342ffbeb4634245a6963094cc9535b6 |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|